Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORLESTRIN FE 2.5/50 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation by suppressing gonadotropin-releasing hormone (Gn RH) via negative feedback on the hypothalamus and pituitary. Increases cervical mucus viscosity to impede sperm penetration and induces endometrial atrophy to prevent implantation.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy (FDA-approved),Treatment of moderate acne vulgaris (in women ≥15 years who desire oral contraception, have no contraindications, and have not achieved success with topical agents),Management of menstrual disorders (off-label)
Prevention of pregnancy (FDA-approved)
One tablet orally once daily, each containing 2.5 mg norethindrone acetate and 50 mcg ethinyl estradiol, plus 7 iron tablets (75 mg ferrous fumarate) taken during the placebo week.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norethindrone: ~8-10 hours (terminal), requiring daily dosing for stable contraceptive effect. Ethinyl estradiol: ~13-21 hours (terminal), supporting once-daily administration.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Hepatic metabolism via cytochrome P450 (CYP) enzymes: ethinyl estradiol is primarily metabolized by CYP3A4; norethindrone undergoes reduction, hydroxylation, and conjugation. Both undergo enterohepatic recirculation and are excreted in urine and feces.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Norethindrone: ~80% renal (as glucuronide and sulfate conjugates), ~20% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal, with enterohepatic recirculation.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethindrone: ~61-70% bound to albumin and SHBG. Ethinyl estradiol: ~97-98% bound to albumin.
~99% bound to serum albumin and sex hormone-binding globulin.
Norethindrone: Vd ~1.8-4.5 L/kg (extensive tissue distribution). Ethinyl estradiol: Vd ~2.5-5 L/kg (distributes into breast milk).
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Norethindrone: ~64% (oral). Ethinyl estradiol: ~38-48% (oral) due to first-pass metabolism.
Oral: ~70% due to first-pass metabolism.
No specific dose adjustment provided; contraindicated in severe renal impairment (GFR <30 m L/min) due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in severe hepatic disease (Child-Pugh class C); use with caution in mild to moderate impairment (Child-Pugh A or B) with monitoring for adverse effects; no specific dose reduction guidelines established.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche; post-menarche: same as adult dosing (one tablet daily) after menstrual cycle establishment.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for postmenopausal women; no dose adjustment in elderly with normal hepatic and renal function, but consider increased risk of thromboembolic events and metabolic effects.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases the risk of serious cardiovascular events (e.g., myocardial infarction, stroke, thromboembolism) from combination oral contraceptive use. Risk increases with age and number of cigarettes smoked. Women over 35 years who smoke should not use this combination oral contraceptive.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thromboembolic disorders: increased risk of venous thromboembolism (VTE) and arterial thrombosis; discontinue if suspected,Cardiovascular disease: increased risk of myocardial infarction and stroke, especially in smokers >35 years,Hypertension: may develop or worsen; monitor blood pressure,Cervical cancer: controversial association; Pap smear screening recommended,Hepatic neoplasia: rare but reported; contraindicated with active liver disease,Gallbladder disease: increased risk of cholelithiasis,Ocular effects: retinal thrombosis may occur; discontinue if sudden partial or complete vision loss,Carbohydrate metabolism: may decrease glucose tolerance; monitor diabetic patients,Fluid retention: use with caution in conditions affected by edema (e.g., migraine, asthma, renal impairment)
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma, endometrial carcinoma, or estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy (known or suspected),Benign or malignant liver tumor (current or history),Active liver disease (e.g., acute viral hepatitis) or impaired liver function,Hypersensitivity to any component of the product,Cigarette smoking in women over 35 years of age
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Avoid grapefruit and grapefruit juice as they may increase estrogen levels and side effects. No specific food restrictions otherwise. Iron from ferrous fumarate may be affected by calcium-rich foods or supplements; take iron at least 2 hours apart from dairy products.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
NORLESTRIN FE 2.5/50 (norethindrone acetate 2.5 mg/ethinyl estradiol 0.05 mg) is contraindicated in pregnancy. First trimester: increased risk of congenital anomalies including cardiovascular and limb defects, and possible non-genital malformations. Second/third trimester: feminization of male fetus, vaginal adenosis, and cervical changes in females. Exposure is associated with a 1.3 to 2.0-fold increased risk of congenital heart defects.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Norethindrone and ethinyl estradiol are excreted into breast milk. M/P ratio for norethindrone is approximately 1.1; for ethinyl estradiol approximately 0.3. Use during lactation may reduce milk production and quality. Not recommended for nursing mothers.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No dosing adjustments are applicable as drug is contraindicated in pregnancy. Higher baseline estradiol levels in pregnancy do not necessitate dose changes because use is not recommended.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
NORLESTRIN FE 2.5/50 contains norethindrone 2.5 mg and ethinyl estradiol 50 mcg, plus ferrous fumarate (75 mg) as a placebo. The high estrogen dose (50 mcg) increases thromboembolic risk; avoid in patients with migraine with aura, hypertension, or smoking >35 years. Iron supplementation can cause dark stools. The formulation includes 7 iron-containing placebo tablets to maintain cycle control and prevent iron deficiency.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time, preferably after an evening meal to reduce nausea.,Missed dose: If one day, take as soon as remembered; if two days, take two tablets then resume schedule; if more, use backup contraception and consult healthcare provider.,Report signs of blood clots: chest pain, sudden shortness of breath, leg pain/swelling, or severe headache.,Iron supplements may cause dark stools; this is harmless.,Do not smoke while taking this medication as it increases risk of serious cardiovascular side effects.,Antibiotics (e.g., rifampin), anticonvulsants, and St. John's Wort may decrease effectiveness; use alternative contraception.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORLESTRIN FE 2.5/50 vs AFIRMELLE, answered by our medical review team.
NORLESTRIN FE 2.5/50 is a Oral Contraceptive that works by Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation by suppressing gonadotropin-releasing hormone (Gn RH) via negative feedback on the hypothalamus and pituitary. Increases cervical mucus viscosity to impede sperm penetration and induces endometrial atrophy to prevent implantation.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORLESTRIN FE 2.5/50 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORLESTRIN FE 2.5/50 is: One tablet orally once daily, each containing 2.5 mg norethindrone acetate and 50 mcg ethinyl estradiol, plus 7 iron tablets (75 mg ferrous fumarate) taken during the placebo week.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORLESTRIN FE 2.5/50 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORLESTRIN FE 2.5/50 is classified as Category C. NORLESTRIN FE 2.5/50 (norethindrone acetate 2.5 mg/ethinyl estradiol 0.05 mg) is contraindicated in pregnancy. First trimester: increased risk of congenital anomalies including car. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.